This is likely the result of the combinatorial effects of PPARγ with other uncharacterized transcriptional regulators, which may represent opportunities for novel therapeutics in T2D and obesity treatment by activating subsets of PPARγ targets that improve insulin sensitization without the negative side-effects associated with TZD treatment. The gene discussed is PPARG; the disease is obesity due to melanocortin 4 receptor deficiency.